
    
      Aim 1: To evaluate the relative in vivo impact of DOR on independent measures of HDL function
      (antioxidant function, cholesterol efflux) compared to integrase inhibitors (raltegravir,
      dolutegravir, elvitegravir, bictegravir) in the setting of TAF backbone in HIV infected
      persons with dyslipidemia.

      Aim 2: To evaluate the relative in vivo impact of DOR on ex vivo atherogenesis
      (monocyte-derived foam cell efflux and chemotaxis) compared to integrase inhibitors
      (raltegravir, dolutegravir, elvitegravir, bictegravir) in the setting of TAF backbone.
    
  